Table 1.
Patient characteristics.
| Total | Histology | CYFRA 21-1 | CEA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non-Squamous NSCLC | Squamous NSCLC | p | ≤3.5 ng/mL | >3.5 ng/mL | p | ≤5.0 ng/mL | >5.0 ng/mL | p | ||
| Age, n | ||||||||||
| <75 | 202 (78.3) | 170 (80.6) | 32 (68.1) | 0.077 | 110 (78.0) | 92 (78.6) | 1.000 | 99 (78.0) | 103 (78.6) | 1.000 |
| ≥75 | 56 (21.7) | 41 (19.4) | 15 (31.9) | 31 (22.0) | 25 (21.4) | 28 (22.0) | 28 (21.4) | |||
| Sex, n. | ||||||||||
| Male | 201 (77.9) | 158 (74.9) | 43 (91.5) | 0.011 | 111 (78.7) | 90 (76.9) | 0.764 | 103 (81.1) | 98 (74.8) | 0.234 |
| Female | 57 (22.1) | 53 (25.1) | 4 (8.5) | 30 (21.3) | 27 (23.1) | 24 (18.9) | 33 (25.1) | |||
| PS, n | ||||||||||
| 0–1 | 224 (86.8) | 184 (87.2) | 40 (85.1) | 0.641 | 133 (94.3) | 91 (77.8) | <0.001 | 114 (89.8) | 110 (84.0) | 0.199 |
| ≥2 | 34 (13.2) | 27 (12.8) | 7 (14.9) | 8 (5.7) | 26 (22.2) | 13 (10.2) | 21 (16.0) | |||
| Smoking status, n | ||||||||||
| Never smoked | 36 (14.0) | 33 (15.6) | 3 (6.4) | 0.108 | 16 (11.3) | 20 (17.1) | 0.209 | 17 (13.4) | 19 (14.5) | 0.858 |
| Current or former | 222 (86.0) | 178 (84.4) | 44 (93.6) | 125 (88.7) | 97 (82.9) | 110 (86.6) | 112 (85.5) | |||
| PD-L1, n | ||||||||||
| <50% | 157 (60.9) | 128 (60.7) | 29 (61.7) | 1.00 | 80 (56.7) | 77 (65.8) | 0.159 | 65 (51.2) | 92 (70.2) | 0.002 |
| ≥50% | 101 (39.1) | 83 (39.3) | 18 (38.3) | 61 (43.3) | 40 (34.2) | 62 (48.8) | 39 (29.8) | |||
| Stage, n | ||||||||||
| IVA | 116 (45.0) | 90 (42.7) | 26 (55.3) | 0.144 | 82 (58.2) | 34 (29.1) | <0.001 | 64 (50.4) | 52 (39.7) | 0.104 |
| IVB | 142 (55.0) | 121 (57.3) | 21 (44.7) | 59 (41.8) | 83 (70.9) | 63 (49.6) | 79 (60.3) | |||
| Treatment line with ICIs, n | ||||||||||
| First-line therapy | 216 (83.7) | 178 (84.4) | 38 (80.9) | 0.520 | 109 (77.3) | 107 (91.5) | <0.005 | 102 (80.3) | 114 (87.0) | 0.178 |
| Second-line or later | 42 (16.3) | 33 (15.6) | 9 (19.1) | 32 (22.7) | 10 (8.5) | 25 (19.7) | 17 (13.0) | |||
| Therapy, n. | ||||||||||
| Anti-PD-1/L1 Ab only | 107 (41.5) | 81 (38.4) | 26 (55.3) | 0.049 | 68 (48.2) | 39 (33.3) | 0.016 | 61 (48.0) | 46 (35.1) | 0.043 |
| Combination therapy | 151 (58.5) | 130 (61.6) | 21 (44.7) | 73 (51.8) | 78 (66.7) | 66 (52.0) | 85 (64.9) | |||
Ab, antibody; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin fraction 21–1; ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; PD-L1, programmed cell death ligand 1; PS, performance status.